Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China, has announced that its next-generation epidermal growth factor receptor (EGFR) inhibitor, sunvozertinib, which received approval in August 2023 for the treatment of EGFR Exon20ins mutated non-small cell lung cancer in China, has achieved sales of RMB 91.29 million (USD 12.6 million) according to the company’s 2023 financial report. Additionally, the firm’s Janus kinase 1 (JAK1) inhibitor, golidocitinib, was granted priority review status in September 2023 for treating relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) in China.
Established in 2017, Dizal has increased its research and development (R&D) spending by 21.23% year-on-year (YOY), investing a total of RMB 806 million into R&D. Despite this increase, the company reported net losses of RMB 1.108 billion, widening from a RMB 736 million net loss in 2022. The company’s workforce has grown to 581 employees as of the reporting period, which is 77.13% more than the same period last year.
Dizal is currently advancing the WU-KONG series studies for sunvozertinib and initiating global multi-center clinical trials for golidocitinib. The pharmaceutical company is also in the development phase for non-covalent LYN/BTK dual target inhibitor DZD8586, intended for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL). Furthermore, DZD6008, a small molecule targeted inhibitor, has been approved for a Phase I study in advanced lung cancer in China as of earlier this month.- Flcube.com
